Meeting
2024 ASCO Annual Meeting
Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
Presenter
Jurriaan Brouwer, PhD
Regeneron Pharmaceuticals, Inc.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT06149286
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS7094)
DOI
10.1200/JCO.2024.42.16_suppl.TPS7094
Abstract #
TPS7094
Poster Bd #
71b
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 ASCO Annual Meeting
A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
Speaker: Laurie Helen Sehn, MD, MPH
Videos & Slides
2021 ASCO Annual Meeting
Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial.
Speaker: Matthew J. Matasar, MD
Videos & Slides
2023 ASCO Annual Meeting
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.
Speaker: Loretta J. Nastoupil, MD
Videos & Slides
2022 ASCO Annual Meeting
inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.
Speaker: Laurie Helen Sehn, MD, MPH